Abiopharma

Johnson & Johnson - Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plusLAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer